Fed Circuit rules against Mylan in patent dispute over epilepsy drug
04-02-2019
sudok1 / iStockphoto.com
The Patent Trial and Appeal Board (PTAB) has upheld a Research Corporation Technologies patent for anti-epileptic drug Vimpat (lacosamide) in a case brought by Argentum Pharmaceuticals.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
PTAB, USPTO, epileptic, patent, IPR, Mylan, Research Corporation Technologies, Argentum Pharmaceuticals